Published in AIDS Weekly, July 14th, 2003
The randomized, double-blind, placebo-controlled trial will enroll approximately 100 sexually active female volunteers who will be treated for 4 weeks. During and at the conclusion of the treatment period, the safety of PRO 2000 will be evaluated based on the presence of both local genital effects and systemic abnormalities.
The trial, which will take place in Kampala, Uganda, is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.